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ABSTRACT Antibody drug conjugates (ADCs) have progressed
from hypothesis to approved therapeutics in less than 30 years, and
the technologies available to modify both the antibodies and the
cytotoxic drugs are expanding rapidly. For reasons well reviewed
previously, the field is trending strongly toward homogeneous,
defined antibody conjugation. In this review we present the anti-
body and small molecule chemistries that are currently used and
being explored to develop specific, homogenous ADCs.
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INTRODUCTION
Antibody drug conjugates (ADCs) are a class of biotherapeutics
that combine the specificity, favorable pharmacokinetics, and
biodistribution of a monoclonal antibody (mAb) with the cyto-
toxic potency of a small-molecule drug. This combination
results in a widened therapeutic window over traditional cancer
chemotherapeutics. Thus, many cytotoxic drugs that are not
amenable to traditional chemotherapy can often be used in the
context of an ADC (1–6).
While the concept of ADCs is in principle a simple one,
their practical implementation is dependent on many factors.
The conjugation method can be as important as the choice of
mAb and cytotoxic drug when designing ADCs, as it poten-
tially impacts efficacy, stability, and toxicity of the resulting
product (7, 8).
Given the scarcity of orthogonally-reactive functional
groups on natural antibodies, current ADCs on the market
are made by conjugating small-molecule cytotoxic drugs to
primary amines in lysines or thiols exposed by reduction of
interchain disulfide bonds, as is the case for the recently
approved ADCs Kadcyla/trastuzumab emtansine/T-DM1
(9) and Adcetris/brentuximab vedotin/SGN-35 respectively
(10, 11).
Though these ADCs improve the therapeutic index of the
original small-molecule drug and improve the potency over
the naked antibody, ADCs made in this manner are hetero-
geneous mixtures, in which each species has different phar-
macological properties. (12). Furthermore, development of
safe and efficacious therapeutics requires their accurate char-
acterization throughout all phases of the discovery, optimiza-
tion, and development life cycle. Since ADCs made by these
conventional conjugation chemistries yield heterogeneous
mixtures that obscure the individual characteristics of each
underlying species, theymake optimization to the best possible
ADC difficult. For example, much discussion has centered on
the optimal number of linker warheads that can be attached to
antibodies, without being detrimental to the original physico-
chemical characteristics. While there will be an approxima-
tion of the maximally tolerable payload of specific linkers and
warheads, the numbers that have been claimed to be optimal
thus far, are based on experimental data with conjugation
chemistries utilizing the natural amino acids. Conjugations to
available lysines and cysteines are stochastic in number and
location, giving a distribution of species with DARs (drug
antibody ratios) ranging between 0 and 9 for loading of
warhead molecules. For example, Kadcyla, is comprised of
the conjugation of an average of 3.4 linker/DM1 warheads
per trastuzumab antibody. In the case of huN901-DM1,
warheads are conjugated to roughly 40 of the 86 lysines within
the trastuzumab antibody sequence corresponding to the
accessible sites (13, 6).
The properties of individual species of ADCs in the product
can vary depending on the number, position and proximity of
the conjugated drugs (7, 8). Cognizant of this, the makers of
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Kadcyla and Adcetris, and the ADC field as a whole, have
migrated toward the development of methods for site-specific
attachment of drugs to antibodies, with the intention of further
improving ADC therapeutics. The real but still modest in-
creases in the therapeutic index that came about from anti-
body conjugation may be further increased by defined, de-
signed, and homogenous conjugation of the cytotoxic drugs to
the antibody. This review aims to give an overview of the
available schemes to generate such homogeneous ADCs.
METHODS TO MAKE HOMOGENOUS ADCS
It has been proven that the site of drug conjugation modulates
stability, PK and therefore efficacy of ADCs (14). The diverse
methods developed to make homogenous ADC can be
grouped in two overarching categories. One general strategy
requires engineering of the antibody primary structure, e.g.
mutation of residues to cysteine or a non-natural amino acids
(nnAA), or insertion of additional amino acids or fusion tags.
The second class uses native antibody sequences and instead
employs novel chemistries and linker strategies to yield site-
specific modification. The antibody engineering based
methods offer the flexibility to mutate or insert tags at multiple
defined positions, in order to directly control the DAR and
determine the optimal sites for conjugation. On the other
hand, methods utilizing native antibodies lack this flexibility
and only allow for limited sites to be conjugated, as deter-
mined by the chosen chemistry. However, since no mutagen-
esis of the antibody is required, such methods offer the advan-
tage of slotting directly into existing antibody production
platforms, allowing for the rapid and efficient conjugation of
any off-the-shelf or de novo antibody, without the need for
proprietary expression platforms.
Homogenous ADC Requiring Antibody Engineering
nnAA Incorporation
On a conceptual level, the production of homogeneous ADCs
with site-specific drug linking requires that the antibody has
one or more unique features that can be exploited for attach-
ment of the warhead. One method of incorporating such
features in an antibody is the utilization of non-natural amino
acids (nnAAs).
In Vivo nnAA Incorporation. In vivo systems that rely on
engineered cell-lines have been utilized for incorporating nnAA
into antibodies to provide bio-orthogonal conjugation handles.
In vivo nnAA incorporation relies on a tRNA and synthetase
(aaRS) pair that is orthogonal to all the endogenous tRNAs and
synthetases in the host cell. The nnAA of choice is supplemented
to themedia during fermentation,making cell-permeability and
stability important considerations for the nnAA. Fundamental-
ly, three approaches based on stop codon suppression have
been developed to enable in vivo incorporation of nnAAs into
antibodies, with amber codon suppression being the most com-
mon (15).
One method relies on a tyrosyl aaRS/tRNA pair from
Escherichia coli, which was engineered to recognize and charge
para-acetyl-phenylalanine (pAcPhe). This engineered aaRS/
tRNA pair was stably integrated in Chinese hamster ovary
cells (16). Subsequent stable integration of light and heavy
chain genes containing the amber stop codon was used to
express antibodies with pAcPhe at designed sites (17). The
keto group of the pAcPhe is reactive towards alkoxy-amines
via oxime coupling and can be conjugated with an alkoxy-
amine containing linker-drug to generate a site-specific ADC.
Ambrx has been an industry leader in in vivo ADC production
using this approach.
Another approach for in vivo nnAA incorporation is based
on the natural amber suppressor tRNA/aaRS pair responsi-
ble for incorporation of pyrrolysine (Pyl) in Methanosarcina
species (18). Here, no engineering of the nnRS/tRNA pair is
required since the system is naturally occurring. Furthermore,
this archea aaRS/tRNA pair is fully orthogonal to both
Escherichia coli and mammalian cells (19, 20). Serendipitously,
the PylRS enzyme is fairly promiscuous in its specificity
towards pyrrolysine, and a variety of chemically function-
alized pyrrolysine derivatives have been shown to be in-
corporated by the enzyme (21, 22). Much like the pAcPhe
based system, the PylRS/tRNA pair can be utilized to
incorporate reactive handles like ketones and azides into
antibodies allowing for site-specific conjugation. This approach
is currently being developed by Allozyne/MedImmune termed
the “AzAbs” (23).
Selenocysteine (Sec) has also been introduced as a chemical
handle in antibodies to generate conjugates via transiently
transfected human embryonic kidney (HEK) 293 F cells (24).
Since Sec is incorporated in naturally occurring systems, no
engineering of the aaRS, tRNA or amino acid is necessary to
make it suitable for ADC generation. Sec incorporation is
accomplished via opal stop codon suppression that is depen-
dent on a selenocystein insertion sequence present on the
mRNA transcript. The demonstration of selecocysteine incor-
poration suggested the potential for site-specific ADCs via
selenides.
Site-specific nnAA incorporation can also be achieved by
replacingmethionine using the sufficiently-promiscuousMetRS.
Cells are made auxotrophic for methionine and engineered to
overexpress MetRS. Supplementation of methionine analogs
into the growth media is used to overcome the 500–2000-fold
reduction in catalytic efficiency (Kcat/Km) of MetRS for the
nnAAs. Further engineering can be carried out to recover
function in the nnAA incorporated proteins (25, 26). So
far this particular approach has been exemplified with E.coli
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expression systems, however, the applicability to ADC pro-
duction has yet to be established.
In Vitro nnAA Incorporation. The approach of nnAA incorpo-
ration into antibodies has also been extended to in vitro
transcription-translation platforms, although titers and scal-
ability limitations were once a concern for cell-free protein
synthesis (CFPS) systems. However, Zawada et al. (27)
engineered an optimized E.coli based cell-free system for pre-
dictable high-yield protein synthesis and folding that showed
scalability over multiple orders of magnitude. E. coli strains
and their extracts were engineered to contain all of the neces-
sary components for transcription, translation and energy
generation from low cost substrates such as glutamate. Addi-
tional improvements upon this CFPS system led to the suc-
cessful expression of antibodies and antibody fragments in the
gram per liter range, in part enabled through overexpression
of chaperones and disulfide isomerases in theE. coli host strain,
fromwhich the cell-free extract is derived (28, 29). In addition,
nnAA incorporation strategies used in in vivo systems can also
be leveraged in in vitro cell-free reactions, with the added
advantage that that the open nature of CFPS systems allows
direct manipulation of the chemical environment in which the
protein synthesis occurs. Consequently, cell-free systems can
overcome constraints of cell permeability and media stability
of the nnAA present in in vivo systems.
Another factor common to most nnAA incorporation sys-
tems is the presence of competing endogenous release factors
(RFs). These RFs naturally recognize certain stop codons and
therefore compete for stop codon suppression of nnAA-
tRNAs. Thus, full length protein production of nnAA con-
taining antibodies can be significantly reduced in titer when
compared to wild-type translation. While removal of the
competing RF1 for amber suppression is therefore desirable,
this is complicated by the fact that simple deletion of the gene
from cells is not tolerated in either microbial or eukaryotic
systems. Nonetheless, efficient non-natural amino acid incor-
poration was achieved by RF1 deletion in E. coli enabled by
compensatory engineering of RF2 (30). In vitro transcription-
translation CFPS platforms offer yet another alternative solu-
tion, which circumvents the growth rate issues that arise when
cell-based systems are subjected to release factor modifications
(31). Several groups have demonstrated that RF1 can be
removed after extract preparation allowing E. coli to have
intact RFs during growth of the biomass. Furthermore, RF1
can also be inhibited in the cell-free reaction. These examples
enabled improved nnAA incorporation at many sites without
reengineering the entire genome to maintain cellular viability
(32–36). Hallam and co-workers (37) successfully demonstrat-
ed that it is feasible to replace wild-type RF1 with an OmpT-
susceptible RF1 in strains of E.coli. During the process of
extract production, RF1 degrades due to exposure to OmpT,
which is localized on the outer membrane and therefore not in
contact with RF1 during normal cellular growth. The result is
a cell-free system that produces nnAA containing proteins at
titers comparable to wild-type, as RF1 function is completely
attenuated.
Thus, CFPS systems can be efficiently leveraged to
produce nnAA containing mAbs for ADC generation.
Recently Zimmerman et.al (38) reported production of
site-specific, aglycosylated ADCs by CFPS using a new
orthogonal synthetase that enables incorporation of a
para-azidomethylphenylalanine (pAMF) followed by
strain-promoted alkyl-azide conjugation (SPAAC) to a
dibenzylcyclooctyne (DBCO) functionalized monomethyl
auristatin F (MMAF) drug (Fig. 1).
To arrive at a synthetase capable of charging pAMF onto
its cognate tRNA, the group screened a library of 1760
Methanococcus jannaschii tyrosyl- tRNA synthetase (M.jann-
TyrRS) active site variants, by cell-free expression of each
synthetase and subsequent screening for its ability to suppress
the amber stop codon in the presence of pAzMeF (38).
Due to the simplified expression format afforded by CFPS
systems, rapid screening of many variants can be enabled in
microtiter formats. By combining CFPS expression and auto-
mated high throughput protein purification techniques,
screening of 100’s of site-specifically labeled ADCs was dem-
onstrated with trastuzumab IgG1 as a base scaffold (Sutro
Biopharma unpublished data). Top sites within the
trastuzumab IgG1 framework were identified based on the
attributes of good suppression efficiency, correct assembly of
IgG, and high conjugation efficiency while maintaining prop-
erties of antigen binding, cell killing, and thermostability. This
overall process allowed positional optimization of non-natural
amino acids to enable discovery and production of single
species ADCs with superior properties and showcases the
advantages of homogenous ADC production.
In addition to the Sutro Bipharma technology,
PeptiDream has developed a cell free protein expression
method. Their Flexizyme system is an in vitro evolved artificial
ribozyme that catalyzes the aminoacylation of any non-
natural amino acid onto any tRNA, thereby functioning as
an artificial aminoacyl-tRNA synthetase that efficiently intro-
duces non-natural amino acids into the growing polypeptide
sequence during a cell-free translation process (39, 40). This
has been integrated with an mRNA display and screening
technique called RaPID (Random non-standard Peptide
Integrated Discovery), and extensive libraries of peptides
have been generated and screened yielding good binding
to a variety of protein targets (41). Recently this work was
extended to generate a bispecific antibody Fab fragment
by introducing p-acetylphenylalanine into an αCD3 Fab
followed by conjugation to hydroxylamino folic acid. Simul-
taneous engagement of the T-cell (via CD3) and tumor cell
(via the folate receptor) suppressed tumor growth in vivo at
5 mg/kg, although regrowth began after 80 days (42). At the
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time of this writing no ADCs have been reported from this
technology.
Engineered Cysteine Conjugation
Another option for site-specific modification of antibodies is
through the use of cysteines. Since all cysteines in a native
antibody are paired in disulfide bonds, free cysteines can be
introduced as site-specific chemical moieties through site di-
rected mutagenesis. Due to the highly reactive nature of
cysteine as a nucleophile, the free thiols can then be selectively
modified through the use of maleimides or other electrophilic
groups. Engineering free cysteines into antibodies for site
directed conjugation has the advantage that no specialized
expression system is needed, as would be the case for nnAA
incorporation. However, hurdles for expression and process-
ing have to be overcome. Cysteines are not tolerated at every
position in an antibody as they may interfere with correct
folding or function, disrupt correct formation of the native
disulfide bonds, or form disulfide bonds with free cysteines in
other proteins. Another challenge in inserting free cysteines
into antibodies is that, even if the antibody is well behaved, the
cysteines are often oxidized by disulfide bond formation with
small molecule thiols present in the cell, such as free cysteine
or glutathione. To liberate the cysteine, the antibody has to be
partially reduced, which may result in reduction of some
native disulfide bonds. Subsequent re-oxidation must then
restore the disulfide bonds to their native configuration, while
leaving the engineered cysteine in the reduced form (43). To
address the issue of antibody folding, Junutula et al. at
Genentech developed a Phage ELISA for Selection of Reac-
tive Thiols (PHESELECTOR), which allows for the selection
of tolerated cysteine substitutions in the context of an antibody
Fab fragment (44). From the PHESELECTOR output, ala-
nine 114 (Kabat numbering) of the heavy chain was deter-
mined to be the optimal site for cysteine modification, giving
rise to Genentech’s THIOMAB platform. Furthermore, pro-
duction of various full length antibodies with the A114C HC
mutation showed that the cysteinemutation was well tolerated
and did not adversely affect antibody function, demonstrating
that the approach is applicable across different antibodies.
Other sites outside the Fab domain have also been used to
create free cysteine containing antibodies (14). Seattle Genet-
ics has an anti-CD33 antibody based on their proprietary
engineered cysteine platform in Phase 1 clinical trials, exem-
plifying the robustness of the approach (45).
Enzymatic Conjugation
Ligating enzymes that have high specificity for one substrate
but relaxed specificity for the second substrate are ideal for
chemoenzymatic synthesis of structurally defined protein con-
jugates. Bacterial enzymes, many originally identified in high-
ly pathogenic species, have proven extraordinarily useful tools
in protein engineering. Mammalian orthologs are either ab-
sent or have different substrate specificities. Moreover, genetic
manipulation and screening of variants, and expression in
non-pathogenic species for in situ or in vitro applications, is
usually straightforward. Mammalian enzymes have also been
re-engineered as biosynthetic tools. The chemoenzymatic
strategies for protein-small molecule conjugation are present-
ed below in the order of the degree of protein perturbation
required, from small (3–6 residues) to medium (12–16 resi-
dues) to large (domain fusions).
A quadruple mutant of trypsin (K60E/N143H/E151H/
D189K), trypsiligase, is capable of both Tyr-Arg cleavage and
fusion of a ligand p-guanidinylphenyl ester (R 4-OGp) onto
the newly-exposed arginine amine. Trypsiligase has been
shown to efficiently label a variety of proteins modified with
an N-terminal YRH tripeptide (Fig. 2). Stoichiometries of the
acyl moieties are quite reasonable (3:1), reactions are complete
within 1 h, and the engineered hydrolase/ligase accepts a
variety of substrates (46).
Streptoverticillium mobaraense transglutaminase, EC 2.3.2.13, is
a stable, Ca+-independent enzyme catalyzing the γ-acyl trans-
fer of glutamine to the ε -amino group of lysine (47, 48).
Chemists at the ETH first observed the selective acylation of
























































Fig. 1 Strain-promoted alkyne-azide coupling (SPAAC) between the inserted non-natural amino acid p-azidomethyl phenylalanine (pAMF) and the
dibenzyloctyne (DBCO)-derivitized auristatin drug forms a triazole ring, forging a stable linkage between the small molecule and the antibody.
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flexible regions of an IgG heavy chain. These sites were the
mutated (and therefore aglycosylated) N to Q mutation sites,
which are highly exposed and available to protein-modifying
enzymes. By using the bacterial transglutaminase (BTG) at
these sites they synthesized homogeneous radioimmunotoxins
that were tumor-uptake selective in vivo (49). Building on these
results, the Rinat/Pfizer team identified a glutamine tag (Q
tag) sequence LLQGA that enabled specific Gln transamina-
tion in the presence of all other protein Gln residues and
introduced this pentapeptide into discrete locations along an
anti-EGFR IgG1 antibody (Fig. 3). Out of 90 sites into which
the sequence was introduced, 12 proved to be amendable to
conjugation of amine-containing small molecules.
Engineering the Q tag into the anti-M1S1 mAb C16, and
subsequent conjugation of monomethyl dolastatin 10
(MMAD) at one heavy chain (HC) and one light chain (LC)
site, facilitated comparison of the two discrete DAR 2 ADCs.
They observed that in the rat model the LC ADC had more
favorable pharmacokinetics. Significantly, they also observed
that a higher therapeutic window for both HC and LC ADCs
could be achieved versus the conventional heterogenous
cysteine-linked maleimidocaproyl ValCitpaAB MMAD con-
jugate. The emphasis in these studies was site-dependent rath-
er than linker chemistry-dependent stability and the impact of
site on overall ADC behavior in vivo (50). Subsequently, it was
determined that naturally-occurring aglycosylated antibodies
gave rise to 1.3% off-target conjugation at the heavy chain
Q295 due to conformational effects: in the native glycosylated
protein the glycosylation would sterically obstruct this
transamination. This exposure effect could be overcome
by the Q295N mutation to achieve a completely homo-
geneous conjugate (51). Thus the Q tag, when presented
at solvent-exposed, enzyme-accessible sites, remains a valu-
able tool for defined homogeneous conjugation. Working
with, rather than around, Q295, Innate Pharma recruits
bacterial transglutaminase to this site in an aglyclosylated
mAb, and introduces the N297S or N297Q mutation to
provide homogeneous, site-specific DAR 2 or 4 aglycosylated
ADCs (Innate Pharma website).
The aldehyde tag represents an entirely different chemistry
for linking. It is crafted along the same principle of enzymatic
recognition of a very small consensus sequences (52).
Formylglycine-generating enzyme (FGE) oxidizes the cysteine
in the CxPxR sequence at N- or C- termini to formyl glycine,
when overexpressed in either mammalian or E. coli cells. This
enables expression of antibodies with specifically-inserted al-
dehydes suitable for bioorthogonal reactions with
alkoxylamines, hydrazines, or Pictet-Spengler-reacting trypt-
amines (Fig. 4) (53).
Site specific in vitro oximination at an internal IgG CTPSR
site has recently been reported, overcoming the requirement
that the aldehyde tag be restricted to the protein N- or C-
terminus. Interestingly, the recombinant Mycobacterium
tuberculosis enzyme, used to affect the Cys to fGly conversion
in this work, was consumed stoichiometrically rather than
reacting catalytically (54). Hydration of the aldehyde in the
milieu of protein labeling can lower the efficiency of these
reactions (55), but nonetheless Redwood Bioscience/Catalent
has successfully developed aldehyde incorporation/reactivity
as its SMARTagTM technology, demonstrating its application
for a variety of highly controlled protein modifications (56).
Protein modification technologies that have been used for
trafficking and biodynamic studies have not to date been used
for generation of ADCs, but one may expect that in the future
many of these will be adapted for drug bioconjugation. Sev-
eral of these are included in this review as an acknowledgment
of their potential.
Sortase A (SrtA) from Staphylococcus aureus, one of the many
related sortases found in a variety of Gram-positive species, is
a transpeptidase (57) that recognizes a C-terminal LPXTG
sequence, cleaves the TG bond, and facilitates—via the
thioacyl enzyme-threonine intermediate—the nucleophilic at-
tack of the incoming protein alpha amine on the threonine. In
protein or peptide ligation, the preferred attacking residue is a
glycine di- or trimer, and early chemical ligation approaches
attached glycines to the small molecule of interest. This
was demonstrated to work for conjugation of folate, PEG,


















Fig. 3 Transglutaminase inserts diverse amines into proteins at suitably exposed glutamines that are embedded in the LLQGA recongition sequence.
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all of which could function with a terminal (Gly)n (58, 59).
Eliminating the requirement for oligoglycine, Matsumoto
and coworkers (60) used purified Lactobacillus plantarum
sortase (SrtLp) to site-specifically append the primary
amine biotinyl-3,6-dioxaoctanediamine to LPQTx se-
quences that were not substrates for SrtA. There are some
limitations to ‘sortagging’ in the context of ADCs: the
conjugation site is restricted to the C-terminus, reaction
kinetics are slow, yields are better with glycine than with
general primary amines and intramolecular lysines can
react to crosslink and aggregate the protein. It has also
been shown that the glycine leaving group can return as a
competing nucleophile, essentially reversing the reaction, un-
less a large (ca 10:1) stoichiometric excess of intended nucleo-
phile is used. (61). Interest in this approach, however, has
prompted creative solutions to many of these impediments,
including the use of threonine esters that are recognized as
substrates and release the far less nucleophilic glycolic acid,
enabling conjugation with a 1:1 stoichiometry (Fig. 5) (62).
Directed evolution of the enzyme using yeast-displayed sortase
mutants resulted in a 140-fold increase in LPETG-
conjugation efficiency (63). Moreover, the potential of
protein-small molecule conjugation using sortase was demon-
strated by the conjugation of an antibody Fab fragment F19
having a C-terminal LPETGG in the heavy chain to a
(Gly)3-DY647 fluorophore (64). A recent adaptation of
sortase demonstrated the irreversible hydrazinolysis of pro-
teins, enabling the fusion of both protein and small mole-
cule hydrazides at the nascent C-terminus (Fig. 6).
Sortagging has been transitioned from a tool for protein
study to a tool for conjugation: with the addition of the second
recognition motif of SrtB, NPQTN (65) a dual warhead ADC
was designed by the NBE Therapeutics Group. Each heavy
chain is C-terminally modified with one antitumor toxin while
each light chain is C-terminally modified with a second toxin.
Examples of pentaglycine maytansine and pentaglycin
auristatins were presented at the 2014 PEGS. The use of
cleavable linkers would in principle allow the (Gly)n to be
universally acceptable in the linker construction since it would
ultimately be separated from the released drug.
The E. coli enzyme biotin ligase (BirA), which recognizes
the 15-amino acid Avi-tag GLNDIEAQKIEWHE and
acylates the embedded lysine with biotin, would at first
glance appear useful only in those research applications
where site-specific biotinylation was important. The Ting
group, however, demonstrated that BirA will accept a
synthetic keto analog of biotin as a substrate, albeit at
reduced reaction kinetics, and in so doing placed BirA in
the same essential category as FGE, i.e. an enzyme capable of
inserting a carbonyl (in this case a ketone) site-specifically into
a protein (Fig. 7). Whereas FGE recognizes a small sequence,
but prefers N- and C-termini, BirA requires a longer se-
quence, but is far less restricted in location along the substrate
protein. Reaction with the installed carbonyl was demonstrat-
ed using fluorescein hydrazide (66).
The pioneering work in the Ting lab on BirA-based liga-
tion (BLINC) proved difficult to apply to neurons, and the
group investigated the potential of E. coli lipoic acid ligase
(LplA, called “LAP”). Mutating this enzyme to LplAW37A to
relax the substrate specificity for the lipoic acid component
enabled installation of diverse reactive moieties as long they

















Fig. 4 Enzymatic conversion of the
cystein thiol to a formyl group















































Fig. 5 The sortase-mediated glycine splicing places the glycine-derivitized small molecule at the C-terminus of the protein; C-terminal threonine esters show
improved reaction kinetcs in this strategy.
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An acceptor sequence GFEIDKVWYDLDA was optimized
to present the embedded lysine for acylation, effectively
converting this lysine into a platform for presenting reactive
groups including halides, azides, aldehydes (71), and trans
cyclooctene (72). Currently both BLINC and LAP technolo-
gies have been used for visualization and cellular protein
studies rather than for therapeutic conjugates.
Fusion Tag Technology
Another strategy for engineering site-specific, homogeneous
ADCs involves fusing entire domains or proteins onto the
antibody sequence and using their activity to achieve labeling.
The most well know such strategy is expressed protein ligation
(EPL), which relies on the activity of a self-splicing intein
protein to activate the C-terminal of the target protein and
therefore allowing formation of a new amide bond with a
peptide, protein or small molecule. Though limited to the C-
terminus of the expressed protein, the intien is self-excising
and leaves only a single cysteine residue scar in the resultant
ligated protein. EPL follows a mechanism of (a) C-terminal
thioester formation from an intein sequence (e.g. Mycobacterium
xenopi Gyr A) that spontaneous undergoes N to S-rearrange-
ment, (b) selected thiol displacement of the intein to give an
activated thioester, (c) thiol exchange of the thioester with an
N-terminal cysteinyl or β-amino mercapto ligand (second pro-
tein, peptide, small molecule), followed by (d) spontaneous N-
to-C rearrangement to an amide bond that forges the covalent
link from the C terminus of the protein of interest to the small
molecule(or ligand), with one intervening cysteine (Fig. 8).
Protein trans-splicing (PTS) uses an intein variant which is
split into two parts, attached to the N- and C- termini of the
partners to be ligated. A similar series of reactions attaches the
2 partners, while excising the intein (73). Intein splicing was
demonstrated to site-specifically biotinylate the C-terminus of
an antibody directed against the tumor antigen fibronectin
ED-B9 (73) and to attach a peptide to an αDEC205 antibody
(74). A recent modification of intein chemistry replaced the
entire intein with an α-hydroxy acid, incorporated using
pyrrolysyl tRNA synthetase, that could be synthetically con-
verted to a C-terminal hydrazide, a function more generally
stable than a thioester, but still a good leaving group for
acylation chemistry (75). Although intein splicing has been
used for site-specifically inserting quantum dots into proteins
(76) and for synthesizing a selenoprotein (77), it has not been
placed in the toolbox of antibody drug conjugation.
Proteins that can function with a significant insertion can
exploit the O6 alkylguanine-DNA-alkyl transferase (AGT)
reaction in which the functional group attached to an O6
benzyl group is covalently attacked by the cysteine on AGT
and thus transferred to the protein-of-interest-AGT fusion
(Fig. 9).
To realize the potential of this reaction, directed evolution
of human AGT was used to arrive at a mutant enzyme with
kinetics comparable to wild type hAGT, while retaining the
promiscuous substrate tolerance for the O-benzyl moiety (78).
Referred to as the SNAP-tag, this 20 kDa fusion has found
wide acceptance for site-specifically modifying proteins for
chemical biology studies and therapeutics. An scFv directed
against the tumor-associated epidermal growth factor recep-
tor (EGFR) was fused to an AGT SNAP-tag and this fusion
protein reacted with a benzyl derivative of the photosensitizer
e-chlorin. The scFv-SNAP-e-chlorin conjugate, at a DAR 1,
was used in photo-immunotherapy experiments against target
and non-target cells and showed strong selectivity, good po-
tency, and dependence on light as well as EGFR expression
for cell killing (79).
Homogenous ADCs from Native Antibodies
All the methods mentioned above to make homogenous











































Fig. 7 BirA accepts biotin-like ketones for incorporation into the recongition sequence, enabling the carbonyl chemistry that allows oxyamine-small molecules to
be inserted into the protein.
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other types of methods don’t require protein mutagenesis
for site-specific conjugation. The biggest advantage of such
methods is to conjugate antibodies at a post-translational
stage, which allows the rapid and efficient conjugation of
any off-the-shelf or de novo antibody.
Crosslinking Two Reduced Cysteines
Instead of using engineered cysteine residues, mAbs can be
partially reduced to break intermolecular disulfide bonds of
the native cysteine thiols followed by bis-alkylation to intro-
duce a three-carbon bridge to which the drug is covalently
attached (Fig. 10). Depending on the degree of reduction,
the numbers of free cysteines for conjugation can be 4 or
8 to generate DARs of 2 and 4 respectively. PolyTherics
demonstrated that the ThioBridge ADCs are more stable
than maleimide ADCs in the presence of human serum
albumin (80).
Similarly, Igenica uses this approach to reduce all intermo-
lecular disulfide bonds, exposing 8 cysteines, and then uses
dibromomaleimide (DBM) to react with the free thiol groups
to produce a dithiomaleimide (DTM) (81, 82). Four cytotoxic
drugs with this bifunctional linker are conveniently attached to
the mAbs by crosslinking the reduced cysteins in the Fab and
hinge regions. To make ADCs with DARs higher than 4,
additional cysteines must be engineered into the mAb.
Glycoengineering
ADCs can also be constructed by attaching the drug to chem-
ically activated sugars, attached to the glycosylated mAb.
These glyco-ADCs are constructed by engineering
glycosyltranserases in order to accommodate chemically
active sugars. Molecules of choice can then be conjugated to
the chemical handle on the sugar moiety. Residues in the
active site of the glycotransferase are mutated to allow the
transfer of the chemically reactive sugar residue.
Using modified galactosyl- and sialyltransferases in vitro,
terminal sialic acids were introduced into native glycans on
Asn-297 of antibodies. Subsequent periodate oxidation then
exposed aldehyde groups, which were used to conjugate
aminooxy functionalized cytotoxic agents via oxime ligation
(Fig. 11) (83). Direct introduction of a keto group was realized
by NCI researchers using a mutant β1,4Gal-T1-Y289L trans-
ferase, 2-(2-oxopropyl) galactose, and a bioincorporation
strategy combined with oximination of the drug-linker (84).
SynAffix reports that their GlycoConnectTM technology in-
volves two distinct steps of (a) enzymatic glycan remodeling
(‘tagging’) and (b) selective chemical conjugation. The enzy-
matic incorporation of different sugars enables different con-
jugation methods: such as azide-containing sugars, thiol-
modified sugars and halogenated sugars (SynAffix website).
Enzymatic Conjugation by Transglutaminase/Engineered
Transglutaminase
As discussed in the section 1.3 on enzymatic conjugation, the
use of bacterial transglutaminase (BTG) allows one to attach
diverse compounds at multiple positions by inserting an
LLQGA tag into antibodies. Deglycosylated mAb can be
attached with amino containing compounds site-specifically
at its Gln295 residue (49). Unfortunately with intact sugar
chain, no Gln residues are available to be reactive with the
BTG active site. Using rational design, Dophen Biomed
engineered a BTG by enlarging the opening of the active




















Fig. 8 A β-mercaptoamine-derivitized small molecule (typically cysteine-modified) can be appended onto a protein via intein splicing, in which the ultimate bond










Fig. 9 SNAP tagging uses guanine as a leaving group, forging a thioether bond to a benzyl-derivitized small molecule, but requiring a substantial additional
polypeptide to be added to the protein undergoing modification.
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catalytic Cys residue of the engineered BTGenzyme. This
enables the direct site-specific conjugation of drug to an
un-modified mAb’s heavy chain constant region at a sur-
face Gln residue (85).
We summarize current methods to make homogenous
ADCs and the highlights of their technologies in Table 1.
Conjugation Chemistries on the Horizon
Biocompatible synthetic reactions are being explored to extend
the toolkit for protein modification. The [3+2] strain-
promoted azide-alkyne cycloaddition (SPAAC) shown in
Fig. 1 was used by University of Georgia researchers in con-
junction with glycoengineering. The azide was incorporated
into the protein on an azido sugar by a mutated galactosyl
transferase. The subsequent reaction with DBCO ligands,
including doxorubicin, followed the same course as the Fig. 1
conjugation chemistry (86). Although none of the chemistries
described below (Fig. 12) have been applied to ADCs as of the
writing of this review, one may look to them for future adap-
tation to antibody conjugation.
Sonogashira cross coupling of a terminal alkyne to an aryl
iodide is in principle a promising bioorthogonal chemistry for
ADCs, since either an iodoPhe or an alkynyl aminoacid could
be used as the site of conjugation. Li et al. (87) took the latter
route, using a homopropargyl glycine auxotrophically
substituted for methionine at the C-terminus of ubiquitin.
The HPG-Ub protein was converted in 30 min to a variety
of aryl-substituted derivatives, in 55–93% yields, in the pres-
ence of a water-soluble (and -compatible) palladium complex
developed in their group. The 50:1 stoichiometry of both
‘catalyst’ and aryl iodide to protein, however, indicate that
further development of this method is necessary before using it
tomake cytotoxic drug conjugates on antibodies. A recent and
impressive extension of Sonogashira reactions in living bacte-


















































Fig. 10 Two solutions to the disulfide re-bridging problem: The thiobridge uses two seuquential reactions and gives rise to a longer, more flexible bridge. The




















Fig. 11 Periodate oxidation of antibody glycans is another strategy to enable carbonyl–directed chemistry.
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Pd(NO3)2 promoter, was reported by Li et al. (88), suggesting
that these developments are attainable. Unfavorable stoichi-
ometry has so far also impeded Suzuki-Miyaura coupling,
which has been utilized for the reaction of iodophenylalanine
in maltose binding protein to small molecule aryl boronates
(89), from becoming a mainstream method for antibody-drug
conjugation.
The facile conversion of thiols to allyl thiols, and the
reactivity of cysteinyl allyl thiols in cross metathesis, promoted
by water–soluble ruthenium catalysts, opened an alternative
route to cysteine conjugation. Initial attempts to modify the
B. lentus subtilisin protein required 10,000:1 stoichiometry of
the small molecule olefin, however, due to a strong tendency
toward self-metathesis. (90, 91). Binder and Raines subse-
quently reduced the stoichiometry to 200:1 (92). Se-allyl
selenocyseine (Seac) gave somewhat improved kinetics, but
nonetheless required 2000:1 small molecule reactant:protein
(93). Given the current interest in thiobridging to obtain
homogeneous ADCs that require no genetic manipulation,
overcoming the hurdles to metathesis would seem a useful
pursuit. Chemists at the ETH have been developing
potassium acyl trifluroborates (KATs) for bioorthogonal reac-
tions with suitable non-natural amino acids (94) and have
recently demonstrated the formation of amide bonds between
a diverse set of KATs and synthetic, but unprotected
peptides bearing the O-carbamoyhydroxylamine func-
tion. (95). The ability to site-specifically incorporate O-
diethylcarbamoyl-hydroxylamine into a protein would
enable conjugation of small molecules to antibodies via an
amide bond.
The pioneering ADCs from the last two decades have
become, in turn, the substrate for further innovation.
Creative small-molecule and protein chemistries, often
co-mingled, are being applied to develop homogeneous,
site-specific conjugates. Analytical and bio-analytical
technologies are achieving higher and higher resolution
to subtend this drive.
Whether derived from a modify-the-antibody side or the
modify-the-linker side, the next generation of ADCs to reach
the clinic is likely to have a dramatically distinct profile as







































potassium acyl trifluroborate (KAT) amidation
Fig. 12 Reactions once considered restricted to synthetic chemistry are being incorporated into the toolkit of bioconjugation. Solubility, stability, and
stoichiometry issues are among the parameters that need to be optimized.
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